Measles virus as an oncolytic vector platform

Current Gene Therapy

Volumn 8, Issue 3, 2008, Pages 162-175

  Blechacz, Boris ^a   Russell, Stephen J ^a  

^a Mayo Clinic   (United States)

Author keywords

Antiviral Antibodies; B Cell Non Hodkin Lymphoma; Glioblastoma multiforme; Immune system; Ovarian Cancer; Signaling lymphocyte activation molecule

Indexed keywords

ALPHA INTERFERON; CARCINOEMBRYONIC ANTIGEN; CD150 ANTIGEN; CD20 ANTIGEN; CD38 ANTIGEN; ECHISTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUDARABINE PHOSPHATE; FOLATE RECEPTOR; FOLATE RECEPTOR ALPHA; GELATINASE A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IODINE 131; MEASLES VIRUS VECTOR; MEMBRANE COFACTOR PROTEIN; NUCLEOCAPSID PROTEIN; PURINE NUCLEOSIDE PHOSPHORYLASE; RIBONUCLEOPROTEIN; SODIUM IODIDE SYMPORTER; STRUCTURAL PROTEIN; VERY LATE ACTIVATION ANTIGEN 5; VIRUS GLYCOPROTEIN; VIRUS ONCOLYSATE; VIRUS PROTEIN; VIRUS PROTEIN H; VIRUS VECTOR;

B CELL LYMPHOMA; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CELL SPECIFICITY; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG TARGETING; FIBROSARCOMA; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOMA; MEASLES VIRUS; MEASLES VIRUS EDMONSTON STRAIN; MEASLES VIRUS EDMONSTON ZAGREB STRAIN; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; REVIEW; SKIN LYMPHOMA; T CELL LYMPHOMA; TRANSGENE; TUMOR IMMUNITY; TUMOR XENOGRAFT; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GENITAL NEOPLASMS, FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNITY, NATURAL; MALE; MEASLES VACCINE; MEASLES VIRUS; NEOPLASMS; ONCOLYTIC VIROTHERAPY;

MEASLES VIRUS; RNA VIRUSES;

EID: 48249118805     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652308784746459     Document Type: Review

References (105)

1. Schneider-Schaulies S, ter Mculen V. Measles virus and immunomodulation: molecular bases and perspectives. Expert Rev Mol Med 30: 1-18 (2002).
2. Update: global measles control and mortality reduction-worldwide, 1991-2001. MMWR Morb Mortal Wkly Rep 52: 471-475 (2003).
3. Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol 4: 900-908 (2006).
4. Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med 86: 277-286 (1954).
5. Hilleman MR, Buynak EB, Weibel RE, Stokes J, Jr., Whitman JE, Jr., Leagus MB. Development and evaluation of the Moraten measles virus vaccine. JAMA 206: 587-590 (1968).
6. Duclos P, Ward BJ. Measles vaccines: a review of adverse events. Drug Saf 19: 435-454 (1998).
7. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 2: 105-106 (1971).
8. Zygiert Z. Hodgkin's disease: remissions after measles. Lancet 1: 593 (1971).
9. Mota HC. Infantile Hodgkin's disease: remission after measles. Br Med J 2: 421 (1973).
10. Grote D, Russell SJ, Comu TI, et al. live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97: 3746-3754 (2001).
11. Peng KW, Ahmann GJ, Pham. L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98: 2002-2007 (2001).
12. Rota JS, Wang ZD, Rota PA, Bellini WJ. Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res 31: 317-330 (1994).
13. Griffin DE, Pan CH, Moss WJ. Measles vaccines. Front Biosci 13: 1352-1370 (2008).
14. Liu X, Bankamp B, Xu W, Bellini WJ, Rota PA. The genomic termini of wild-type and vaccine strains of measles virus. Virus Res 122:78-84 (2006).
15. Zuniga A, Wang Z, Liniger M, et al. Attenuated measles virus as a vaccine vector. Vaccine 25: 2974-2983 (2007).
16. Live attenuated measles vaccine. EPI Newsl. 2: 6 (1980).
17. Radecke F, Spielhofer P, Schneider H, et al. Rescue of measles viruses from cloned DNA. EMBO J 14: 5773-5784 (1995).
18. Rager M, Vongpunsawad S, Duprex WP, Cattaneo R. Polyploid measles virus with hexameric genome length. EMBO J 21: 2364-2372 (2002).
19. Cattaneo R, Kaelin K, Baczko Y, Billeter MA. Measles virus editing provides an additional cysteine-rich protein. Cell 56: 759-764 (1989).
20. Bellini WJ, Englund G, Rozenblatt S, Arnheiter H, Richardson CD. Measles virus P gene codes for two proteins. J Virol 53: 908-919 (1985).
21. Cattaneo R, Rebmann G, Schmid A, Baczko K, ter Meulen V, Billeter MA. Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J 6: 681-688 (1987).
22. Cathomen T, Naim HY, Cattaneo R. Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol 72: 1224-1234 (1998).
23. Nussbaum O, Broder CC, Moss B, Stern LB, Rozenblatt S, Berger EA. Functional and structural interactions between measles virus hemagglutinin and CD46. J Virol 69: 3341-3349 (1995).
24. Wild TF, Fayolle J, Beauverger P, Buckland R. Measles virus fusion: role of the cysteine-rich region of the fusion glycoprotein. J Virol 68: 7546-7548 (1994).
25. Wild TF, Malvoisin E, Buckland R. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol 72 (Pt 2): 439-442 (1991).
26. Baker KA, Dutch RE, Lamb RA, Jardetzky TS. Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell 3: 309-319 (1999).
27. von Messling V, Milosevic D, Devaux P, Cattaneo R. Canine distemper virus and measles virus fusion glycoprotein trimers: partial membrane-proximal ectodomain cleavage enhances function. J Virol 78: 7894-7903 (2004).
28. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406: 893-897 (2000).
29. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75: 295-305 (1993).
30. Naniche D, Varior-Krishnan G, Cervoni F, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 67: 6025-6032 (1993).
31. Hashimoto K, Ono N, Tatsuo H, et al. SLAM (CD150)-independent measles virus entry as revealed by recombinant virus expressing green fluorescent protein. J Virol 76: 6743-6749 (2002).
32. Andres O, Obojes K, Kim KS, ter Meulen V, Schneider-Schaulies J. CD46- and CD150-independent endothelial cell infection with wild-type measles viruses. J Gen Virol 84: 1189-1197 (2003).
33. Nakamura T, Peng KW, Harvey M, et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23: 209-214 (2005).
34. Dhiman N, Jacobson RM, Poland GA. Measles virus receptors: SLAM and CD46. Rev Med Virol 14: 217-229 (2004).
35. Veillette A, Latour S. The SLAM family of immune-cell receptors. Curr Opin Immunol 15: 277-285 (2003).
36. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40: 109-123 (2003).
37. Schneider U, von Messling V, Devaux P, Cattaneo R. Efficiency of measles virus entry and dissemination through different receptors. J Virol 76: 7460-7467 (2002).
38. Erlenhofer C, Duprex WP, Rima BK, ter Meulen V, Schneider-Schaulies J. Analysis of receptor (CD46, CD150) usage by measles virus. J Gen Virol 83: 1431-1436 (2002).
39. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 64: 4919-4926 (2004).
40. Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng KW. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol 81: 13149-13157 (2007).
41. Ong HT, Timm MM, Greipp PR, et al. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 34: 713-720 (2006).
42. Dingli D, Peng KW, Harvey ME, et al. Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun 337: 22-29 (2005).
43. Iankov ID, Blechacz B, Liu C, et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 15: 114-122 (2007).
44. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 14: 324-333 (2007).
45. Haralambieva I, Iankov I, Hasegawa K, Harvey M, Russell SJ, Peng KW. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther 15: 588-597 (2007).
46. Grandvaux N, tenOever BR, Servant MJ, Hiscott J. The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis 15: 259-267 (2002).
47. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 14: 778-809 (2001).
48. Garcia-Sastre A. Mechanisms of inhibition of the host interferon alpha/ beta-mediated antiviral responses by viruses. Microbes Infect 4: 647-655 (2002).
49. Palosaari H, Parisien JP, Rodriguez JJ, Ulane CM, Horvath CM. STAT protein interference and suppression of cytokine signal transduction by measles virus V protein. J Virol 77: 7635-7644 (2003).
50. Shaffer JA, Bellini WJ, Rota PA. The C protein of measles virus inhibits the type I interferon response. Virology 315: 389-397 (2003).
51. Takeuchi K, Kadota SI, Takeda M, Miyajima N, Nagata K. Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett 545: 177-182 (2003).
52. Devaux P, von Messling V, Songsungthong W, Springfeld C, Cattaneo R. Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology 360: 72-83 (2007).
53. Ohno S, Ono N, Takeda M, Takeuchi K, Yanagi Y. Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. J Gen Virol 85: 2991-2999 (2004).
54. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 9: 961-966 (2002).
55. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97: 339-345 (2001).
56. Grote D, Cattaneo R, Fielding AK. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res 63: 6463-6468 (2003).
57. Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 63: 2462-2469 (2003).
58. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 62: 4656-4662 (2002).
59. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103: 1641-1646 (2004).
60. Blechacz B, Splinter PL, Greiner S, et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 44: 1465-1477 (2006).
61. Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res 60: 6396-6402 (2000).
62. Spitzweg C, Morris JC. Approaches to gene therapy with sodium/iodide symporter. Exp Clin Endocrinol Diabetes 109: 56-59 (2001).
63. Heinzerling L, Kunzi V, Oberholzer PA, Kundig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 106: 2287-2294 (2005).
64. Kunzi V, Oberholzer PA, Heinzerling L, Dummer R, Naim HY. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. J Invest Dermatol 126: 2525-2532 (2006).
65. McDonald CJ, Erlichman C, Ingle JN, et al. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat 99: 177-184 (2006).
66. Liu C, Sarkaria JN, Petell CA, et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 13: 7155-7165 (2007).
67. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Noninvasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 8: 527-531 (2002).
68. Peng KW, Hadac EM, Anderson BD, et al. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther 13: 732-738 (2006).
69. Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res 61: 3501-3507 (2001).
70. Hasegawa Y, Pham L, O'Connor MK Federspiel MJ, Russell SJ, Peng KW. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 12: 1868-1875 (2006).
71. Schneider U, Bullough F, Vongpunsawad S, Russell SJ, Cattaneo R. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol 74: 9928-9936 (2000).
72. Hallak LK, Merchan JR, Storgard CM, Loftus JC, Russell SJ. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res 65: 5292-5300 (2005).
73. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571 (1994).
74. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164 (1994).
75. Kumar CC. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4: 123-131 (2003).
76. Kumar CC, Nie H, Rogers CP, et al. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. J Pharmacol Exp Ther 283: 843-853 (1997).
77. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 75: 2087-2096 (2001).
78. Russell SJ, Hawkins RE, Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 21: 1081-1085 (1993).
79. Russell SJ, Cosset FL. Modifying the host range properties of retroviral vectors. J Gene Med 1: 300-311 (1999).
80. Zhao Y, Zhu 1, Lee S, et al. Identification of the block in targeted retroviral-mediated gene transfer. Proc Natl Acad Sci USA 96: 4005-4010 (1999).
81. Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ. Oncolytic measles viruses displaying a single-chain antibody against CD38, a mycloma cell marker. Blood 101: 2557-2562 (2003).
82. Bucheit AD, Kumar S, Grote DM, et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 7: 62-72 (2003).
83. Ungerechts G, Springfeld C, Frenzke ME, et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 15: 1991-1997 (2007).
84. Peng KW, Holler PD, Orr BA, Kranz DM, Russell SJ. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor. Gene Ther 11: 1234-1239 (2004).
85. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 24: 419-466 (2006).
86. Germain RN. The T cell receptor for antigen: signaling and ligand discrimination. J Biol Chem 276: 35223-35226 (2001).
87. Nakamura T, Peng KW, Vongpunsawad S, et al. Antibody-targeted cell fusion. Nat Biotechnol 22: 331-336 (2004).
88. Lecouturier V, Fayolle J, Caballero M, et al. Identification of two amino acids in the hemagglutinin glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46 downregulation: phenotypic markers that differentiate vaccine and wild-type MV strains. J Virol 70: 4200-4204 (1996).
89. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol 78: 302-313 (2004).
90. Xie M, Tanaka K, Ono N, Minagawa H, Yanagi Y. Amino acid substitutions at position 481 differently affect the ability of the measles virus hemagglutinin to induce cell fusion in monkey and marmoset cells co-expressing the fusion protein. Arch Virol 144: 1689-1699 (1999).
91. Hadac EM, Peng KW, Nakamura T, Russell SJ. Reengineering paramyxovirus tropism. Virology 329: 217-225 (2004).
92. Hasegawa K, Nakamura T, Harvey M, et al. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 12: 6170-6178 (2006).
93. Allen C, Vongpunsawad S, Nakamura T, et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 66: 11840-11850 (2006).
94. Paraskevakou G, Allen C, Nakamura T, et al. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther 15: 677-686 (2007).
95. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56: 1067-1084 (2004).
96. Zhao XB, Lee RJ. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv Drug Deliv Rev 56: 1193-1204 (2004).
97. Peng KW, Frenzke M, Myers R, et al. Biodistribution of oncolytic measles virus after intraperitoneal admin stration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther 14: 1565-1577 (2003).
98. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172 (1991).
99. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383-1387 (2000).
100. Giannini C, Sarkaria JN, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7: 164-176 (2005).
101. Ungerechts G, Springfeld C, Frenzke ME, et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 67: 10939-10947 (2007).
102. Alkhatib G, Roder J, Richardson C, et al. Characterization of a cleavage mutant of the measles virus fusion protein defective in syncytium formation. J Virol 68: 6770-6774 (1994).
103. Springfeld C, von Messling V, Frenzke M, Ungerechts; G, Buchholz CJ, Cattaneo R. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 66: 7694-7700 (2006).
104. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 11: 479-491 (2006).
105. Mrkic B, Pavlovic J, Rulicke T, et al. Measles virus spread and pathogenesis in genetically modified mice. J Virol 72:7420-7427 (1998).